Home » today » Health » Orange: new blood

Orange: new blood

By






Photo credit © Orange

(Boursier.com) — Orange rose by 1% to 10.80 euros, while the operator’s Board of Directors, which met on March 30, unsurprisingly proposed the appointment of Jacques Aschenbroich as the group’s new director and as Chairman of the Board from May 19. The appointment of Jacques Aschenbroich as director will be submitted to the vote of the General Meeting of shareholders on May 19, after which the Board will meet to elect the non-executive Chairman of the Group.

In addition, the Board took two other decisions relating to its governance. First of all, he proposes the appointment as new administrator of Valerie Beaulieu-James, General Manager Sales & Marketing and member of the Executive Committee of the Adecco group. She will replace Helle Kristoffersen who leaves the Board after eleven years during which she participated in its work with a strong involvement and she was able to bring to the Board throughout her mandate her great expertise in the files studied, in particular in the field of technology. .
The Board also decided, on the proposal of Christel Heydemann, Chief Executive Officer of Orange from April 4, 2022, to renew the term of office of Ramon Fernandez as Deputy Chief Executive Officer, his current term of office ending with the separation of the functions on April 4, 2022. April. He will thus continue to bring his expertise and experience to the group.

Among the latest brokers’ opinions, Barclays has revised its price target downwards, from 10 to 9 euros… The group forecasts growth of 21% per year in its FCF over 2022-2023 (i.e. 500-600 ME) , among the three biggest increases in the sector and after almost a decade of decline, thanks to the current management plan, a cycle of possible value-creating transactions and a new managerial cycle with the arrival of new blood in management …


©2022 Boursier.com



Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.